Dual blockade of mitogen-activated protein kinases ERK-1 (p42) and ERK-2 (p44) and cyclic AMP response element binding protein (CREB) by neomycin inhibits glioma cell proliferation.

Abstract

Several growth factors and their receptors are expressed in inappropriately high abundance in gliomas and are further upregulated during the transition from low- to high-grade malignancy. In glioma cells growth factors induce expression of mitogen-activated protein kinase (MAPK) pathways. Here we report that neomycin restrained glioma cell proliferation in vitro by inhibition of p42/44 MAPK and the cyclic AMP element binding protein (CREB)-directed transcription pathways. Since alteration of gene transcription by inhibition of specific transcriptional regulatory proteins has important therapeutic potential, neomycin offers great promise for treating cancer and other diseases associated with a sustained MAPK activity.

• Authors: Pedro Cuevas, Diana Diaz-González, Fernando Carceller, Manuel Dujovny
• Journal: Neurological research (Neurol Res) Vol. 25 Issue 1 Pg. 13-6 (Jan 2003) ISSN: 0161-6412 [Print] England
• PMID: 12564119 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclic AMP Response Element-Binding Protein
• Protein Synthesis Inhibitors
• Mitogen-Activated Protein Kinase 1
• Mitogen-Activated Protein Kinase 3
• Mitogen-Activated Protein Kinases
• Neomycin

Topics

• Animals
• Cell Division (drug effects)
• Cyclic AMP Response Element-Binding Protein (antagonists & inhibitors, drug effects, metabolism)
• Glioma (metabolism)
• Immunohistochemistry
• Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors, drug effects, metabolism)
• Mitogen-Activated Protein Kinase 3
• Mitogen-Activated Protein Kinases (antagonists & inhibitors, drug effects, metabolism)
• Neomycin (pharmacology)
• Protein Synthesis Inhibitors (pharmacokinetics)
• Rats
• Tumor Cells, Cultured